Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia

Pars, Kaweh; Garde, Niklas; Skripuletz, Thomas; Pul, Refik; Dengler, Reinhard; Stangel, Martin

doi:10.1002/mus.23895

Cited by 31 publications

(26 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, reports on SCIg treatment in other neuromuscular disorders (MG and IBM) are rare. Pars and colleagues reported SCIg effects on dysphagia in IBM patients [Pars et al 2013]. As far as we know reports of SCIg effects in treating MG are lacking.…”

Section: Discussionmentioning

confidence: 99%

“…High-dose intravenous immunoglobulin (IVIg) is considered an evidence-based treatment in acute inflammatory demyelinating polyneuropathy, chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), while positive therapeutic responses have also been reported in patients with myasthenia gravis (MG) [European Federation of Neurological Societies, 2008]. In addition, IVIg seems to be effective in inclusion body myositis (IBM)-associated dysphagia [Dalakas et al 1997;Pars et al 2013].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders

Yoon

Gold

Kerasnoudis

2015

Ther Adv Neurol Disord

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders

Yoon

Gold

Kerasnoudis

2015

Ther Adv Neurol Disord

View full text Add to dashboard Cite

show abstract

“…The subcutaneous administration of Ig has been initiated in these diseases [11–14]; few studies have reported the safety and efficacy of SCIg [15, 16]. …”

Section: Discussionmentioning

confidence: 99%

High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis

Chérìn

Delain

Crave

et al. 2014

Case Reports in Rheumatology

View full text Add to dashboard Cite

Polymyositis is a rare debilitating condition characterized by chronic inflammation and muscle weakness. Standard treatments include corticosteroids and immunosuppressants; however, resistance to these regimens may develop. Intravenous immunoglobulins (IVIg) are thus recommended for patients with drug-resistant polymyositis. The patient presented a resistant polymyositis with severe muscle weakness, increasing dysphagia, and significant loss in weight. Subcutaneous immunoglobulins (SCIg) were initiated after failure of steroids and immunosuppressive drugs. SCIg was given twice per week (2 then 1.3 g/kg/month). Clinical recovery was observed within 2 months after the SCIg initiation. After several injections, the patient showed a progressive improvement in muscle strength. Serum creatine kinase activity decreased to normal levels, and dysphagia was resolved. The SC injections were generally well tolerated and good patient satisfaction was reported. This promising observation suggests that SCIg may be useful in active and refractory polymyositis.

show abstract

“…Then, the patient switched to SCIg (0.77 g/kg/month) and swallowing and body weight was constant over 4 years of follow up, preventing parental nutrition [19]. Also Cherin P, et al reported 6 cases regarding patients affected by IBM describing a resolution of dysphagia with SCIg treatment [20].…”

Section: Discussionmentioning

confidence: 99%

A Case of Refractory Dysphagia in the Context of Polymyositis Treated with Subcutaneous Immunoglobulin and Review of the Literature

Vacchi¹

2017

Clin Med Rev Case Rep

View full text Add to dashboard Cite

Polymyositis (PM) is a systemic inflammatory disease affecting muscles and several other organs, including gastrointestinal system, in which the main symptom is dysphagia.Here, we describe a case of a 57-years-old woman presenting a difficult-to-manage dysphagia related to polymyositis, treated with benefit with Subcutaneous Immunoglobulins (SCIg). Beyond symptomatic therapies, immunosuppressive therapies (glucocorticoids, methotrexate, azathioprine, mycophenolatemofetil, and cyclosporine) are the main treatment of PM related dysphagia. Nowadays, few data are available to evaluate effectiveness and safety of intravenous immunoglobulins on esophageal involvement in refractory PM and only anecdotal cases are reported about the use of SCIg in the treatment of dysphagia in inflammatory myopathies (including inclusion body myositis). Up to date, this is the second observation describing an improvement of dysphagia in a subject affected by PM treated with SCIg; further studies are needed to evaluate the effectiveness of SCIg in the management of these patients.

show abstract

Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia

Cited by 31 publications

References 13 publications

Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders

Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders

High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis

A Case of Refractory Dysphagia in the Context of Polymyositis Treated with Subcutaneous Immunoglobulin and Review of the Literature

Contact Info

Product

Resources

About